Untitled Document

L. Patrick Gage, Ph.D.
Chairman
Dr. Gage is the interim chief executive officer and director of PDL BioPharma, a public biotechnology company. Dr. Gage has held a variety of positions with Flagship Ventures since 2003. He also serves as chairman of Adnexus Therapeutics, Inc., a private biopharmaceutical company, and as a director of three private companies, Acceleron Pharma Inc., Immune Control Inc. and Alvine Pharmaceuticals Inc. Dr. Gage is an advisor to Functional Genetics, Inc., Perkin Elmer, Inc. and Warburg Pincus LLC. Dr. Gage served as senior vice president, science and technology, at Wyeth from 2001 to 2002, and as president of Wyeth Research from 1998 to 2002. Prior to Wyeth, Dr. Gage held positions of increasing responsibility at Genetics Institute, culminating with his service as president after the company was acquired by Wyeth. He also spent 18 years at Hoffman-La Roche, Inc. in various scientific and management positions. Dr. Gage also serves as a director the Biotechnology Institute. He has a B.S. in physics from the Massachusetts Institute of Technology and a Ph.D. from the University of Chicago.

Brian H. Dovey
Mr. Dovey is a managing member of Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, and has served in this capacity with the firm since 1988. He has served as chairman of three companies and on the board of directors of some 30 additional companies, including BAS Medical, Inc., Ocera Therapeutics, Inc., Orexigen Therapeutics, Inc., Orqis Medical Corporation, REVA Medical, Inc. and SkinMedica, INc.. Prior to joining Domain, Mr. Dovey spent six years at Rorer Group, Inc. (now Aventis), including as president from 1986 to 1988. Previously, he was president of Survival Technology, Inc., a start-up medical products company. He also held management positions with Howmedica, Inc., Howmet Corporation, and New York Telephone. Mr. Dovey has served as both president and chairman of the National Venture Capital Association. He is the chair of the board of managers of the Wistar Institute. Mr. Dovey received his B.A. from Colgate University and an M.B.A. degree from the Harvard Business School.

William F. Hamilton, Ph.D.
Dr. Hamilton has served on the University of Pennsylvania faculty since 1967, and is the Landau Professor of Management and Technology, and director of the Jerome Fisher Program in Management and Technology at The Wharton School and the School of Engineering and Applied Science. He serves as a director of Neuronyx Inc., NovaDel Pharma Inc., Avid Radiopharmaceuticals, Inc. and Yaupon Therapeutics, Inc. Dr. Hamilton received his B.S. and M.S. in chemical engineering and his M.B.A. from the University of Pennsylvania, and his Ph.D. in applied economics from the London School of Economics.

Douglas J. MacMaster, Jr.
Mr. MacMaster served as Senior Vice President of Merck & Co., Inc. from 1988 until his retirement in 1992, where he was responsible for worldwide chemical and pharmaceutical manufacturing, the Agvet Division, and the Specialty Chemicals Group. From 1985 to 1988, Mr. MacMaster was president of the Merck Sharp Dohme Division of Merck. Mr. MacMaster serves as a director of Martek Biosciences Corp., a public biological products manufacturing company. He received his B.A. from St. Francis Xavier University, and his J.D. from Boston College Law School.

H. Stewart Parker
Ms. Parker is the president and chief executive officer of Targeted Genetics Corporation, a public biotechnology company, and has held various positions with the company since its founding in 1993. From 1981 to 1992, she held various positions at Immunex Corporation, most recently as vice president, corporate development. From 1991 to 1993, Ms. Parker served as president, chief executive officer and director of Receptech Corporation. She serves on the board of directors and the executive committee of the Biotechnology Industry Organization, and as a director of several privately-held companies and not-for-profit organizations. Ms. Parker received her B.A. and M.B.A. from the University of Washington.

Mark H. Rachesky, M.D.
Dr. Rachesky has served as the president, as well as the founder, of MHR Management LLC and affiliates, investment managers of various private investment funds that invest in inefficient market sectors, including special situation equities and distressed investments, since 1996. From 1990 through June 1996, Dr. Rachesky was employed by Carl C. Icahn, initially as a senior investment officer, and for the last three years as sole managing director of Icahn Holding Corporation and acting chief investment advisor. Dr. Rachesky serves as non-executive chairman of the board of Loral Space & Communications, Inc. and Leap Wireless International, Inc. He also serves as a director of NationsHealth Inc. and Emisphere Technologies, Inc. Dr. Rachesky is a graduate of Stanford University School of Medicine and Stanford University School of Business. Dr. Rachesky graduated from the University of Pennsylvania with a major in Molecular Aspects of Cancer.

George J. Vergis, Ph.D.
Dr. Vergis has served as president and chief executive officer of Neose Technologies, Inc. since May 2006, and as a director since February 2006. He joined Neose as vice president, business and commercial development in July 2001, and served most recently as president and chief operating officer. From 1996 to 2001, Dr. Vergis served as vice president, new product development and commercialization at Knoll Pharmaceutical Company, a division of BASF Pharma, responsible for the commercial planning, product development, and marketing for the cardiovascular, immunology, and critical care franchises. Prior to BASF, Dr. Vergis held a variety of clinical and medical marketing positions at Wyeth-Ayerst Laboratories and Warner Lambert Parke Davis. Dr. Vergis serves as a director of Woods Services, a not-for-profit organization. Dr. Vergis received his B.A. in biology and history from Princeton University, his Ph.D. in physiology from the Pennsylvania State University and an M.B.A. from Columbia University.